New Clinical Trials Could Provide Answer to Spinal Injuries

Australian clinical trials are set to begin for a groundbreaking spinal injury treatment using a “bridge” made from patients’ own nasal stem cells.

This research, led by Griffith University’s Professor James St John, focuses on using olfactory ensheathing cells, which naturally regenerate every six-to-eight weeks, to repair damaged spinal cords. The innovative approach contrasts with previous efforts by creating bridges of nerve cells placed directly over the injury site, allowing for better integration and support.

Earlier trials, like that of Darek Fidyka in 2014, showed some success, but faced challenges with cell purity and transplantation methods. These issues have been addressed by Professor St John’s team through the creation of high-purity bridges of cells that have already started forming connections before surgery.

The upcoming trials will involve 30 participants, with 20 receiving the cell bridges along with intensive rehabilitation, while the remaining 10 will receive only rehabilitation. The primary goal is to determine safety, but researchers hope to see functional improvements such as enhanced movement or sensation.

If successful, this treatment could pave the way for broader applications in treating brain injuries or neurodegenerative diseases. While the road ahead is long, these tests represent a significant step towards a potential cure for spinal cord injuries.